Patients
NSCLC, tumor, PDAC
TUMOR, NSCLC
Patients were aged ≥ 18 years and had histologically/cytologically confirmed CRC, PDAC, or NSCLC; ≥ 1 measurable lesion per RECIST v1.1 [All patients provided written, informed consent to participate in the study, including consent to provide archived tumor specimens from core biopsy or larger resection < 3 years from screening for biomarker studies. All patients were requested to provide optional consent for paired pretreatment and on-treatment tumor biopsies where clinically feasible (as determined by the treating physician). The study protocol was approved by the institutional review board or ethics committee for each participating center, and the study was run in accordance with ethical principles originating in the Declaration of Helsinki and consistent with the International Conference on Harmonization guidelines on Good Clinical Practice, as well as applicable regulatory requirements.